10:32 AM EDT, 06/16/2025 (MT Newswires) -- Centessa Pharmaceuticals ( CNTA ) said Monday it has received clearance for its investigational new drug application from the US Food and Drug Administration to start a phase 1 clinical trial of ORX142 in healthy participants.

The company said it is developing ORX142 to treat select neurological and neurodegenerative disorders.

Centessa said it will evaluate the safety, tolerability, and pharmacokinetics of single-ascending doses and multiple-ascending doses of ORX142 in the participants, adding that it intends to start the first-in-human phase 1 clinical trial this year.

Shares of the company were down 1.5% in recent Monday trading.

Price: 12.20, Change: -0.18, Percent Change: -1.46